Mito Akiko, Yamasaki Masahiro, Matsuura Kanji, Kajihara Toshiki, Nitta Tomoko, Awaya Hirokazu, Arita Ken-Ichi, Kashiwado Kozo, Ohashi Nobuyuki
Dept. of Respiratory Disease, Hiroshima Red Cross Hospital and Atomic Bomb Survivors Hospital.
Gan To Kagaku Ryoho. 2009 Oct;36(10):1653-6.
The aim of this study was to evaluate retrospectively chemotherapy of weekly carboplatin and paclitaxel with concurrent radiation therapy for patients with locally advanced non-small cell lung cancer (NSCLC).
Between January 2000 and March 2008, 38 patients were treated by chemotherapy with carboplatin and paclitaxel once a week, repeated for 6 weeks, with thoracic radiation therapy of 1 or 2 times a day on weekdays. After concurrent chemoradiotherapy, we planned consolidation chemotherapy of carboplatin(AUC 5-6)and weekly paclitaxel(70- 80 mg/m(2)) on day 1, 8 and 15, when possible.
The enrolled patients were 31 men and 7 women, with the median age of 59 years (39-76 years), stage III A/III B: 10/28, Ad/Sq/AdSq/Un: 17/17/2/2. The response rate of this chemoradiotherapy was 78. 9%. The median survival time and time to progression were 24. 7 months and 8. 1 months, respectively. Grade 3 or 4 hematological toxicities during concomitant chemoradiotherapy were leukocytopenia(5. 2%)and neutropenia(5. 2%). Grade 3 or 4 non-hematological toxicities were esophagitis(2. 6%)and pneumonitis (5. 2%). There was a therapy-associated death by radiation pneumonitis.
Carboplatin and paclitaxel with concurrent radiation therapy for a patient with stage III NSCLC showed a good response with relatively mild side effects. We reached the conclusion that concurrent chemoradiotherapy would be a useful choice for locally advanced non-small cell lung cancer on the practical clinic.
本研究旨在回顾性评估每周一次卡铂和紫杉醇化疗联合同期放疗用于局部晚期非小细胞肺癌（NSCLC）患者的疗效。
2000年1月至2008年3月期间，38例患者接受每周一次卡铂和紫杉醇化疗，共重复6周，并在工作日每天进行1或2次胸部放疗。同步放化疗后，如有可能，计划在第1、8和15天进行卡铂（AUC 5 - 6）和每周一次紫杉醇（70 - 80 mg/m²）的巩固化疗。
入组患者中男性31例，女性7例，中位年龄59岁（39 - 76岁），ⅢA/ⅢB期：10/28例，腺癌/鳞癌/腺鳞癌/未分化癌：17/17/2/2例。该放化疗方案的有效率为78.9%。中位生存时间和疾病进展时间分别为24.7个月和8.1个月。同步放化疗期间3或4级血液学毒性为白细胞减少（5.2%）和中性粒细胞减少（5.2%）。3或4级非血液学毒性为食管炎（2.6%）和肺炎（5.2%）。有1例因放射性肺炎导致的治疗相关死亡。
卡铂和紫杉醇联合同期放疗用于Ⅲ期NSCLC患者显示出良好疗效且副作用相对较轻。我们得出结论，在实际临床中，同步放化疗对于局部晚期非小细胞肺癌将是一种有用的选择。
